Based on the earnings call transcript, Merck demonstrated solid execution and resilience despite facing patent expiries and market challenges. Key positives include maintaining revenue levels despite Singulair patent loss, continued growth in key franchises like Januvia/Janumet, strong emerging markets performance (especially China), and multiple potential near-term product launches. However, there are some concerns around gross margin pressure from product mix shifts, increased SG&A investments needed for launches, and the delay of odanacatib filing to 2014. Management's confident tone and clear strategic focus on both near-term execution and pipeline advancement suggest the company is well-positioned to navigate current challenges while building for future growth.

[1]